87 related articles for article (PubMed ID: 17050794)
41. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes.
Hellum BH; Hu Z; Nilsen OG
Basic Clin Pharmacol Toxicol; 2009 Jul; 105(1):58-63. PubMed ID: 19371257
[TBL] [Abstract][Full Text] [Related]
42. Effects of Seijo-bofu-to, a traditional Japanese herbal medicine containing furanocoumarin derivatives, on the drug-metabolizing enzyme activities in healthy male volunteers.
Saruwatari J; Takashima A; Yoshida K; Soraoka H; Ding TB; Uchiyashiki Y; Tsuda Y; Imamura M; Oniki K; Miyata K; Nakagawa K
Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):360-5. PubMed ID: 24612940
[TBL] [Abstract][Full Text] [Related]
43. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.
May DG; Porter J; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1994 May; 55(5):492-500. PubMed ID: 8181193
[TBL] [Abstract][Full Text] [Related]
44. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs.
Islam M; Frye RF; Richards TJ; Sbeitan I; Donnelly SS; Glue P; Agarwala SS; Kirkwood JM
Clin Cancer Res; 2002 Aug; 8(8):2480-7. PubMed ID: 12171873
[TBL] [Abstract][Full Text] [Related]
45. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.
Ozdemir V; Naranjo CA; Herrmann N; Shulman RW; Sellers EM; Reed K; Kalow W
J Clin Psychopharmacol; 1998 Feb; 18(1):55-61. PubMed ID: 9472843
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome.
Flockhart DA; Clauw DJ; Sale EB; Hewett J; Woosley RL
Clin Pharmacol Ther; 1994 Oct; 56(4):398-405. PubMed ID: 7955801
[TBL] [Abstract][Full Text] [Related]
47. Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease.
Black C; May G; Csuka ME; Lupoli S; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1992 Dec; 52(6):659-67. PubMed ID: 1458774
[TBL] [Abstract][Full Text] [Related]
48. Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
Trousil S; Lee P; Edwards RJ; Maslen L; Lozan-Kuehne JP; Ramaswami R; Aboagye EO; Clarke S; Liddle C; Sharma R
Br J Pharmacol; 2019 Sep; 176(18):3712-3722. PubMed ID: 31236938
[TBL] [Abstract][Full Text] [Related]
49. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.
Hutzler JM; Wienkers LC; Wahlstrom JL; Carlson TJ; Tracy TS
Arch Biochem Biophys; 2003 Feb; 410(1):16-24. PubMed ID: 12559973
[TBL] [Abstract][Full Text] [Related]
50. Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers.
Hakooz N; Hamdan I
Curr Drug Metab; 2007 Jan; 8(1):9-15. PubMed ID: 17266520
[TBL] [Abstract][Full Text] [Related]
51. Effects of dietary broccoli on human drug metabolising activity.
Kall MA; Vang O; Clausen J
Cancer Lett; 1997 Mar; 114(1-2):169-70. PubMed ID: 9103281
[TBL] [Abstract][Full Text] [Related]
52. The disposition of dapsone in cirrhosis.
May DG; Arns PA; Richards WO; Porter J; Ryder D; Fleming CM; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1992 Jun; 51(6):689-700. PubMed ID: 1611807
[TBL] [Abstract][Full Text] [Related]
53. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism.
Kall MA; Vang O; Clausen J
Carcinogenesis; 1996 Apr; 17(4):793-9. PubMed ID: 8625493
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenomic biomarkers in dermatologic drugs.
Greenfield NP; Maibach H
J Dermatolog Treat; 2013 Dec; 24(6):408-10. PubMed ID: 22646507
[TBL] [Abstract][Full Text] [Related]
55. Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer.
Fleming CM; Persad R; Kaisary A; Smith P; Adedoyin A; Porter J; Wilkinson GR; Branch RA
Pharmacogenetics; 1994 Aug; 4(4):199-207. PubMed ID: 7987404
[TBL] [Abstract][Full Text] [Related]
56. AmineDB: large scale docking of amines with CYP2D6 and scoring for druglike properties--towards defining the scope of the chemical defense against foreign amines in humans.
Costache AD; Trawick D; Bohl D; Sem DS
Xenobiotica; 2007 Mar; 37(3):221-45. PubMed ID: 17624022
[TBL] [Abstract][Full Text] [Related]
57. Gender differences in pharmacokinetics.
Gleiter CH; Gundert-Remy U
Eur J Drug Metab Pharmacokinet; 1996; 21(2):123-8. PubMed ID: 8839685
[TBL] [Abstract][Full Text] [Related]
58. Abdiction/addiction connection.
Hood E
Environ Health Perspect; 2005 Dec; 113(12):A812-4. PubMed ID: 16330337
[No Abstract] [Full Text] [Related]
59. Deprescribing in Older Poly-Treated Patients Affected with Dementia.
Gareri P; Gallelli L; Gareri I; Rania V; Palleria C; De Sarro G
Geriatrics (Basel); 2024 Feb; 9(2):. PubMed ID: 38525745
[TBL] [Abstract][Full Text] [Related]
60. Safety and Tolerability of Antimicrobial Agents in the Older Patient.
Soraci L; Cherubini A; Paoletti L; Filippelli G; Luciani F; Laganà P; Gambuzza ME; Filicetti E; Corsonello A; Lattanzio F
Drugs Aging; 2023 Jun; 40(6):499-526. PubMed ID: 36976501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
